Neuroprotective effect of vinpocetine against 3-NP induced reduction of body weight and oxidative stress in rats

International Journal of Phytomedicine

Volumn 3, Issue 3, 2011, Pages 362-369

  Ratra, Meenakshi ^a   Sharma, Pl ^b   Gupta, Rajesh ^a  

^a Sri Sai College of Pharmacy   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

3 Nitropropionic acid; Huntington disease; Vinpocetine

Indexed keywords

3 NITROPROPIONIC ACID; MALONALDEHYDE; PHOSPHODIESTERASE I; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HUNTINGTON CHOREA; LIPID PEROXIDATION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; WEIGHT REDUCTION;

EID: 84859856483     PISSN: None     EISSN: 09750185     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vonsattel JP, DiFiglia M. Huntington disease, J. Neuropathol Exp Neurol 1998;57:369-384.
2. Martin JB. and Gusella JF. Huntington's disease: pathogenesis and management. N Engl J. Med 1986; 315: 1267-1276.
3. Cruz, V and Santamaria, A. Integrative Hypothesis for Huntington's disease: A Brief Review of Experimental Evidence. Physiol. Res 2007; 56: 513-526.
4. La Fontaine MA, Geddes JW, Banks A and Butterfield DA. Effect of exogenous and endogenous antioxidants on 3- nitropropionic acid - induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem 2000; 75: 1709-1715.
5. Kumar P, Padi SSV, Naidu PS and Kumar A. Possible Neuroprotective of Curcumin in Attenuating 3-Nitropropionic Acid - Induced Neurotoxicity. Methods Find. Exp. Clin. Pharmacol 2006; 17: 485-92.
6. KimYJ, Yi, Y Sapp, Wang Y, Cuiffo B, Kegel, Qin ZH, Aronin, DiFiglia, M. Capase3- cleaved N- terminal fragments of wild type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, undergo calpain - dependent proteolysis. Proc. Natl. Acad Sci. U.S.A.2001; 98: 12784-12789.
7. Vis JC, Van Huizen RT, Veerbeek MM, de Waal RM, ten Donkelaar HJ and Kremer B. Creatine protects against 3- nitropropionic acid-induced cell death in murine corticostriatal slice cultures. Brain Res 2004; 1024: 16-24.
8. Beal MF. Mitochondrial dysfunction in neurodegenerative disease. Biochem Biophy Acta 1998; 1366: 211-223.
9. Nagakura M, Oosumi K, Hirano H, Onishi Y. Pharmcogenomics and therapeutics trategies for Dementia. Science direct 2002; 34:357-379.
10. Puzzo D, Vitolo O, Trinchese F, Joel P, Jacob AP, Arancio. Neurobiology of Disease Amyloid β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity. J Neuroscience 2005; 25: 6887-6897.
11. Fujita SS, Zghb J, Hong. Species differences in Brain phosphodiesterase levels. J Neural Transm 2008; 41:185.
12. Nibuya M, Nestler EJ,Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
13. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inihibitor. Biochem Biophys Rest Commun 1999; 19:20-24.
14. Song, Perides, and Liu YF. Expression of full length polyglutamine expanded Huntington distrupt growth factor receptor signaling in rat. J Biolchem 1997; 277:6703-6707.
15. Bishop VS, DM Farrell. The role of cGMP and cAMP in active thermoregulatory vasodilation. Neurobiol Dis 1997; 272: R975-R981.
16. O'Donnell JM and Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase. Trends Pharmacol. Sci 2004; 25: 158-163.
17. K Tarnok, E Kiss, PGM Luiten, C Nyakas, K Tihanyi, K Schlett, and ULM Eisel. Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Curr Pharm Des 2008; 66: 63-65.
18. Lugnier C: Cyclic nucleotide phosphodiesterase superfamily. Pharmacol Ther 2006; 109:366-398.
19. Wills ED. Mechanism of lipid peroxide formation in animal. Biochems J. 1966; 99: 667-676.
20. Kumar P, Padi SSV, Naidu PS and Kumar A. Effect of resveratrol on 3- nitropropionic acid- induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav. Pharmacol, 2006, 17: 485-492.
21. Rose GM, Hopper A, De Vivo M and Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005; 11(26): 3329-3334.
22. Vas A and Gulyas D. Eburnamine derivatives and the brain. Med Res Ev 2005; 25: 737-57.
23. Kaudac D and Mittlemon A, Serpico R, Sinha AA, Natale C, Pani P, Simone S and Farber E. Cell death: apoptosis versus necrosis. Int J on col 2002; 21: 165-70.
24. Koutouzis TK, Borlongan, Scorcia and Creese PR, Systemic 3-NP: long term effects on locomotor behavior. Brain Res 1994; 646:242-46.
25. Tunez I, Montilla P, Munoz and Tariq MC. Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3- nitropropionic acid in synaptosomes. Pharmacology 2005; 74:113-118.
26. Borlongan CV, Freeman TK, DW Cahill. Behavioral pathology induced by repeated injection of 3-NP mimic the symptoms of HD. Brain Res 1995; 697: 254-257.
27. Borlongan CV, Kanning K, Freeman. Free radical damage and oxidative stress in Huntington's disease. JFLA Med Assoc 1996; 83: 335-41.
28. Haik KL, Haik, DA, Shear Sabel, Dunbar GL, Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of HD. Exp Neurol 2000; 163: 430-439.
29. Kodsi, Swerdlow. Mitochondrial 3-NP produce abnormalities in rats that model of HD. Depart Psych 1997; 231: 103-07.
30. Sun Y. Free radicals and antioxidant enzymes. Free Radic Biol Med 1990; 8: 583-99.
31. Stolc S. Indole derivatives as neuroprotectants. Life Sci 1950; 65: 1943-50.
32. Santos MS, Durate AL, Oliveria. Synaptosomal response to oxidative stress: effects of Vinpocetine. Free Radic Res 2000; 32: 57-66.s